A targeted gene panel illuminates pathogenesis in young people with unexplained kidney failure
Authors:
- Felicity BealFBFelicity Beal
- Charlotte BebbCBCharlotte Bebb
- Fiona BeecroftFBFiona Beecroft
- Emma BurkittEBEmma Burkitt
- Deirdre CilliersDCDeirdre Cilliers
- Abhijit DixitADAbhijit Dixit
- 5 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 37 (5) , 1273-1284
Abstract
Background Kidney failure in young people is often unexplained and a significant proportion will have an underlying genetic diagnosis. National Health Service England pioneered a comprehensive genomic testing service for such circumstances accessible to clinicians working outside of genetics. This is the first review of patients using this novel service since October 2021, following its introduction into clinical practice. Methods The ‘Unexplained Young-Onset End-Stage Renal Disease’ (test-code R257) gene panel uses targeted next generation sequencing to analyse 175 genes associated with renal disease in patients under 36 years of age. All tests undertaken between October 2021 and February 2022 were reviewed. Phenotypic data were extracted from request forms and referring clinicians contacted where additional details were required. Results Seventy-one patients underwent R257 testing over the study period. Among them, 23/71 patients (32%) were confirmed to have a genetic diagnosis and 2/71 (3%) had a genetically suggestive variant. Nephronophthisis and Alport syndrome were the most common conditions identified, (4/23 (17%) with pathogenic variants in NPHP1 and 4/23 (17%) with pathogenic variants in COL4A3/COL4A4). Positive predictors of a genetic diagnosis included a family history of renal disease (60% of positive cases) and extra-renal disease manifestations (48% of positive cases). Conclusion This is the first study to evaluate the R257 gene panel in unexplained young-onset kidney failure, freely accessible to patients meeting testing criteria in England. A genetic diagnosis was identified in 32% of patients. This study highlights the essential and expanding role that genomic testing has for children and families affected by renal disease today. Graphical abstractKeywords
Funding Information
- Nephrotic Syndrome Trust (Medical Research Council precision medicine grant MR/R013942)
- Medical Research Council (MR/Y008340/1)
This publication has 22 references indexed in Scilit:
- Peri-mortem evaluation of infants who die without a diagnosis: focus on advances in genomic technologyJournal of Perinatology, 2018
- Genetic risk of APOL1 and kidney disease in children and young adults of African ancestryCurrent Opinion in Pediatrics, 2018
- Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosisKidney International, 2018
- Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disordersKidney International, 2017
- Advances in renal genetic diagnosisCell and tissue research, 2017
- Early Requirement for RRT in Children at Presentation in the United Kingdom: Association with Transplantation and SurvivalClinical Journal of the American Society of Nephrology, 2016
- Co-Inheritance of Functional Podocin Variants with Heterozygous Collagen IV Mutations Predisposes to Renal FailureNephron, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- What do we know about chronic renal failure in young adults? I. Primary renal diseasePediatric Nephrology, 2009
- Nephronophthisis-Associated CiliopathiesJournal of the American Society of Nephrology, 2007